FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
OMB Number:	3235-028				
Estimated average bu	rden				
hours per response	0.9				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1 37	pe Response	~)													
Name and Address of Reporting Person * Goodwin Bradford S				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/21/2014							e title below)	Oth	er (specify below)		
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(Cit	y)	(State)	(Zip)			Ta	ble I	- Non-Der	vative Securitie	s Acquire	d, Disposed	of, or Bene	ficially Own	ed	
1.Title of S (Instr. 3)	Security		2. Transaction Date (Month/Day/Year)	2A. Dec Executi any (Month	on Da	ate, if C	Trar ode instr.	8) (Amount (D)	of (D) Ov Tra			d	Ownership of Borm:	eneficial wnership
		separate line for each						Persor in this	s who respon form are not r	equired to	o respond	unless the		ned SEC 14	74 (9-02)
			Table II -						osed of, or Bene onvertible secur		wned				
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transac Code	tts, cal	lls, warr 5. Numb	er ative s d (A) sed	options, co	onvertible securercisable and Date	ities)	nd Amount ying	8. Price of Derivative Security (Instr. 5)	Securities Beneficially Owned Following Reported Transaction	Ownership Form of Derivative Security: Direct (D) or Indirect (s) (I)	Beneficia
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	tts, cal	5. Number of Deriva Securitie Acquired or Disposof (D) (Instr. 3,	er ative s d (A) sed	options, co	envertible securercisable and Date y/Year) Expiration	7. Title ar of Underl Securities	nd Amount ying	Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported	Ownership Form of Derivative Security: Direct (D) or Indirect	of Indirect Beneficia Ownersh

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
Goodwin Bradford S C/O RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X				

Signatures

/s/Dolly Vance (Attorney-in-Fact)	05/21/2014
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares vest monthly for twelve (12) months from the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.